Psychedelics Genetic Test

Your psychedelics genetic profile with personalized reports and actionable insights, delivered directly to your smartphone.

Classical Psychedelics: Understand your sensitivity to classical psychedelics and serotonin response
Ketamine Metabolism: Discover your ketamine response based on genetics and format
Mental Health Risk: Explore your short- and long-term risk factors associated with psychedelics use
Future Updates: Latest research and studies, recommendations and exclusive offers

Out of stock

$89
Free Shipping

Add to cart

Your serotonin sensitivity

The way your body responds to classical psychedelics such as psilocybin, LSD and DMT, is influenced by the HTR2A gene. This gene influences the baseline expression of the 5-HTR2A receptor, which binds to serotonin and releases neurotransmitters in the brain. These neurotransmitters can cause potential hallucinations and other mental effects of the classical psychedelic "trip".

20% of people carry an HTR2A genetic variant which can increase receptor density, potentially making them more susceptible to stronger hallucinogenic effects. These individuals should be more cautious when considering classical psychedelic therapies.

Classical psychedelics report includes

Insight into serotonin response and how it can affect a "trip"
Genetics by population and ethnicity
How serotonin receptor density can also influence SSRI drug response and much more

Your response to ketamine

The way your body responds to ketamine is influenced by the BDNF gene. This gene influences the secretion of brain-derived neurotrophic factor (BDNF) protein, which is released when being dosed with ketamine. BDNF helps with the growth and maintenance of new neurons and synapses that are necessary for normal mood and brain connectivity. Stress and anxiety inhibit the production of BDNF which can lead to mood disorders such as PTSD and depression.

30% of people carry the BDNF 'Met' genetic variant that can cause impaired secretion of BDNF. These individuals are more likely to have a decreased response to the antidepressant effects of ketamine therapy.

Ketamine response report includes

Insight into how the BDNF gene can affect ketamine response
Genetics by population and ethnicity

Your metabolism of ketamine

The way your body metabolizes ketamine, a fast-acting anesthetic with hallucinogenic properties, is influenced by the CYP2B6 gene. This gene encodes a liver enzyme that helps metabolize ketamine in your bloodstream. 10–20% of people carry the CYP2B6*6 genetic variant which causes them to metabolize ketamine up to 2x to 3x slower than normal.

These ‘slow metabolizers’ should be more cautious when being dosed with ketamine, as they will likely experience an increased duration and intensity of effect, especially when taking ketamine in intravenous or subcutaneous form.

Ketamine metabolism report includes

Insight into intensity and duration of effects
Genetics by population and ethnicity
How metabolism can vary by ketamine format and much more

Your metabolism of LSD, MDMA, ayahuasca

The way your body metabolizes LSD, MDMA and ayahuasca, is influenced by the CYP2D6 gene. This gene encodes a liver enzyme that helps metabolize these drugs in your bloodstream. 5–10% of people carry the CYP2D6 genetic variant which causes them to metabolize LSD, MDMA and ayahuasca up to 2x slower than normal.

Individuals with the ‘poor metabolizer’ phenotype should be more cautious when being dosed with LSD, MDMA or ayahuasca, as they will likely experience an increased duration and intensity of effect when taken in oral form.

LSD, MDMA, ayahuasca metabolism report includes

Insight into intensity and duration of effects
Genetics by population and ethnicity
Metabolizer phenotype and much more

Your risk for psychedelics-related mental health effects

Genetics play an important role in your short- and long-term risk for mental health effects such as schizophrenia and psychosis. The NRG1, DISC1 and C4A genes have all shown to influence your genetic risk for these effects.

Studies have shown that misuse of psychedelics combined with genetic risk factors can increase the risk of negative mental health effects.

Mental health risk report includes

Short-term risk of adverse psychedelic-induced effects
Long-term risk of psychosis and schizophrenia
Genetics by population and ethnicity

Future updates and exclusive benefits

Explore your psychedelics genetic profile and more.

In addition to your reports, we're constantly updating our platform to bring you future insights and benefits including:
Tools and recommendations to better understand your psychedelics profile
The latest science and research news
Exclusive offers from our partners

Want to know more?

Learn How It Works

Your use of our services and the information provided through this website, including test results and reports, is for informational purposes only, and is not intended for medical advice or treatment, or for other therapeutic or diagnostic use. Before taking any action based on this information, you must consult an experienced healthcare professional. Your use of our services and this website is governed by the laws of the Province of Ontario and the federal laws of Canada. © 2022 HaluGen Life Sciences. All rights reserved.